AUR-105 by Aurigene Oncology for Leukemia: Likelihood of Approval

Check­point Ther­a­peu­tics’ an­ti-PD-L1 an­ti­body has been turned down by the FDA due to man­u­fac­tur­ing is­sues, send­ing its share price down 45% pre­mar­ket on Mon­day. The

LB Phar­ma­ceu­ti­cals, a schiz­o­phre­nia biotech de­vel­op­ing a new ver­sion of a decades-old med­i­cine, has closed a $75 mil­lion Se­ries C raise and it be­gan a